Sector News

Eli Lilly inks OpenAI deal for Discovering New Antibiotics

June 29, 2024
Life sciences

Eli Lilly is teaming up with OpenAI on a quest to develop new treatments that overcome antimicrobial resistance (AMR).

The Big Pharma will use the generative artificial intelligence from OpenAI to come up with new solutions for microbial infections. Financial details of the deal, which was announced June 25, were not disclosed.

“Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies in the battle against drug-resistant pathogens,” Diogo Rau, executive vice president and chief information and digital officer at Lilly, said in a press release.

AMR is a global public health threat driven by the misuse and overuse of the drug class. Resistance can be exacerbated by poverty and inequality, especially in low- and middle-income countries, according to Lilly.

The new partnership marks one of Lilly’s several commitments to the cause via its Social Impact Venture Capital Portfolio. The portfolio was launched in 2020 and has contributed $100 million to the AMR Action Fund, a VC working to bring two to four new antibiotics to market by 2030. Just this month, the AMR fund put its money behind Elion Therapeutics in an $81 million series B that will support the company’s clinical-stage antifungal therapy.

By Gabrielle Masson


comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach